ERBB2 and cancer: The application of HER2-targeting BSABs has exhibited promising efficacy in patients with G/GEJ cancers (ORR, 44.4–55.6%) or BTC (ORR, 47%) who presented with high HER2 expression or previously received HER2-targeted therapy [129–131, 142].